Skip to main content
SpringerLink
Log in

Treatment of Chronic Myocardial Ischemia: Rationale and Treatment Options

  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Abstract

A rational approach to the treatment of chronic myocardial ischemia requires an appreciation of the pathophysiology of coronary artery disease and the treatment options available. Any factor that causes an imbalance between myocardial oxygen supply and demand can provoke ischemia. Myocardial oxygen requirements rise with increases in heart rate, contractility, or left ventricular wall stress. Myocardial oxygen supply is determined by coronary artery flow and myocardial oxygen extraction. Anti-anginal medications are the mainstay of anti-ischemic management and act to correct the balance between myocardial supply and demand by increasing coronary blood flow, reducing myocardial oxygen requirements, or both. These medications include nitrates (which act principally by venous vasodilation, but also probably by coronary dilation), beta-blockers (which act mainly by reducing heart rate and cardiac contractility), and calcium channel blockers (which act principally by arterial and coronary vasodilation). The choice of therapy and its effectiveness depend on the underlying cause of ischemia. The complimentary mechanisms of action of these drug classes suggest that their use in combination may result in a greater reduction in myocardial oxygen demand than that achieved with monotherapy. In addition, the pharmacological actions of some of these drugs may serve to offset the undesirable side effects associated with others, for example, the reflex tachycardia produced by some calcium channel blockers may be offset by beta-blocker therapy. Finally, aspirin and lipid-lowering drugs and the potential role for anti-oxidants must also be considered in combination therapy. Invasive techniques for myocardial ischemic management, such as coronary artery bypass and coronary angioplasty, improve myocardial oxygen supply by relieving or circumventing the atherosclerotic obstruction responsible for ischemia. Surgery is the preferred technique in patients with certain medical condi tions, for example, those with triple-vessel disease, but is not recommended in patients with mild angina unless left main artery disease is present.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Selwyn AP, Yeung AC, Ryan TJ, Raby KE, Barry J, Ganz P. Pathophysiology of ischemia in patients with coronary artery disease. Prog Cardiovasc Dis 1992;35:27–39.

    Google Scholar 

  2. Maseri A. Role of coronary artery spasm in symptomatic and silent myocardial ischemia. J Am Coll Cardiol 1987;9: 249–262.

    Google Scholar 

  3. Cohn PF. Silent myocardial ischemia. Ann Intern Med 1988; 109:312–317.

    Google Scholar 

  4. Nesto RW, Zarich SW, Kowalchuk GJ, Kenigsberg AE, Shurmur SW, McAuliffe LS. Frequency of symptoms suggestive of dynamic coronary artery disease in patients referred for coronary angiography. Am J Cardiol 1989;64: 1374–1376.

    Google Scholar 

  5. Muller JE, Abela GS, Nesto RW, Tofler GH. Triggers, acute risk factors and vulnerable plaques: The lexicon of a new frontier. J Am Coll Cardiol 1994;23:809–813.

    Google Scholar 

  6. Cohn PF. Prognosis in exercise-induced silent myocardial ischemia and implications for screening asymptomatic populations. Prog Cardiovasc Dis 1992;34:399–412.

    Google Scholar 

  7. Lim R, Dyke L, Dymond DS. Effect on prognosis of abolition of exercise-induced painless myocardial ischemia by medial therapy. Am J Cardiol 1992;69:733–735.

    Google Scholar 

  8. Pepine CJ, Cohn PF, Deedwania PC, et al. for the ASIST Study Group. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life: The Atenolol Silent Ischemia Study (ASIST). Circulation 1994; 90:762–768.

    Google Scholar 

  9. Superko RH, Krauss RM. Coronary artery disease regression: Convincing evidence for the benefit of aggressive lipoprotein management. Circulation 1994;90:1056–1069.

    Google Scholar 

  10. Kramsch DM, Sharma RC. Limits of lipid-lowering therapy: The benefits of amlodipine as an anti-atherosclerotic agent. J Hum Hypertens 1995;9(Suppl. I):S3–S9.

    Google Scholar 

  11. CASS Principal Investigators and their Associates. Coronary Artery Surgery Study (CASS): A randomized trial of coronary artery bypass surgery, survival data. Circulation 1983;68:939–950.

    Google Scholar 

  12. Passamani E, Davis KB, Gillespie MJ, Killip, T. A randomized trial of coronary artery bypass surgery: Survival of patients with a low ejection fraction. N Engl J Med 2985;312: 1665–1671.

  13. Taylor HA, Deumite NJ, Chaitman BR, Davis KB, Killip T, Rogers WJ. Asymptomatic left main coronary artery disease in the Coronary Artery Surgery Study (CASS) Registry. Circulation 1989;79:1171–1179.

    Google Scholar 

  14. RITA Trial Participants. Coronary angioplasty versus coronary artery bypass survey: The Randomised Intervention Treatment of Angina (RITA) trial. Lancet 1993;341:573–580.

    Google Scholar 

  15. Chan P, Heo J, Garibian G, Askenase A, Segal BC, Iskandrian AS. The role of nitrates, beta-blockers, and calcium antagonists in stable angina pectoris. Am Heart J 1988;116: 838–848.

    Google Scholar 

  16. Thadani U. Medical therapy of stable angina pectoris. Cardiol Clin 1991;9:73–87.

    Google Scholar 

  17. Loscalzo J. Antiplatelet and antithrombotic effects of organic nitrates. Am J Cardiol 1992;70:18B–22B.

    Google Scholar 

  18. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chandhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987;84:9265–9269.

    Google Scholar 

  19. Abshagen U, Betzien G, Endele R, Kaufmann B, Neugebauer G. Pharmacokinetics and metabolism of isosorbide-dinitrate after intravenous and oral administration. Eur J Clin Pharmacol 1985;27:637–644.

    Google Scholar 

  20. Parker JO, Fung HL. Transdermal nitroglycerin in angina pectoris. Am J Cardiol 1984;54:471–476.

    Google Scholar 

  21. Zimrin D, Beichek N, Bogin KT, et al. Antianginal effects of intravenous nitroglycerin over 24 hours. Circulation 1988; 77:1376–1384.

    Google Scholar 

  22. Thadani U, Fung HL, Darke AC, Parker JO. Oral isosorbide dinitrate in angina pectoris during acute and sustained therapy. Am J Cardiol 1982;49:411–419.

    Google Scholar 

  23. Deedwania PC, Carbajal EV, Nelson JR, Hait H. Anti-ischemic effects of atenolol versus nifedipine in patients with coronary artery disease and ambulatory silent ischemia. J Am Coll Cardiol 1991;17:963–969.

    Google Scholar 

  24. Portegies MCM, Sijbring P, Gobel EJAM, Viersma JW, Lie KI. Efficacy of metoprolol and diltiazem in treating silent myocardial ischemia. Am J Cardiol 1994;74:1095–1098.

    Google Scholar 

  25. Von Arnim T and the TIBBS Investigators. Medical treatment to reduce total ischemic burden: Total Ischemic Burden Bisoprolol Study (TIBBS), a Multicenter Trial Comparing Bisoprolol and Nifedipine. J Am Coll Cardiol 1995;25: 231–238.

    Google Scholar 

  26. Hoekenga D, Abrams J. Rational medical therapy for stable angina pectoris. Am J Med 1984;76:309–314.

    Google Scholar 

  27. Deanfiteld JE, Detry J-MRG, Lichtlen PR, Magnani B, Sellier P, Thaulow E, for the CAPE Study Group. Amlodipine reduces transient myocardial ischemia in patients with coronary artery disease: Double-Blind Circadian Anti-Ischemia Program in Europe (CAPE Trial). J Am Coll Cardiol 1994; 24:1460–1467.

    Google Scholar 

  28. Russek HI. Propranolol and isosorbide dinitrate: Synergism in angina pectoris. Am J Cardiol 1968;121:44–45.

    Google Scholar 

  29. Akhras F, Jackson G. Efficacy of nifedipine and isosorbide mononitrate in combination with atenolol in stable angina. Lancet 1991;338:1036–1039.

    Google Scholar 

  30. Cohn PF, Vetrovec GW, Nesto R, Gerber FR. The Nifedipine Total Ischemia Awareness Program: A national survey of painful and painless myocardial ischemia including results of anti-ischemic therapy. Am J Cardiol 1989;63:534–539.

    Google Scholar 

  31. Kawanishi DT, Reid CL, Morrison EC, Rahimtoola SH. Response of angina and ischemia to long-term treatment in patients with chronic stable angina: A double-blind randomized individualized dosing trial of nifedipine, propranolol and their combination. J Am Coll Cardiol 1992;19:409–417.

    Google Scholar 

  32. Davies RF, Habibi H, Klinke WP, et al., for the Canadian Amlodipine/Atenolol in Silent Ischemia Study (CASIS) Investigators. Effect of amlodipine, atenolol and their combination on myocardial ischemia during treadmill exercise and ambulatory monitoring. J Am Coll Cardiol 1995;25:619–625.

    Google Scholar 

  33. Knatterud GL, Bourassa MG, Pepine CJ, et al., for the ACIP Investigators. Effects of treatment strategies to suppress ischemia in patients with coronary artery disease: 12-week results of the Asymptomatic Cardiac Ischemia Pilot (ACIP) Study. J Am Coll Cardiol 1994;24:11–20.

    Google Scholar 

  34. Mahony C. Effect of aspirin on myocardial ischemia. Am J Cardiol 1989;64:387–389.

    Google Scholar 

  35. Nyman I, Larsson H, Wallentin L. Prevention of serious cardiac events by low-dose aspirin in patients with silent myocardial ischemia. Lancet 1992;340:497–501.

    Google Scholar 

  36. Davey Smith G, Song F, Sheldon TA. Cholesterol lowering and mortality: The importance of considering initial level of risk. Br Med J 1993;306:1367–1373.

    Google Scholar 

  37. Street DA, Comstock GW, Salkeld RM, Scheup W, Klag MJ. Serum antioxidants and myocardial infarction: Are low levels of carotenoids and alpha tocopherol risk factors for myocardial infarction? Circulation 1994;90:1154–1161.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Cardiology, State University of New York Health Sciences Center, Stony Brook, New York, USA

    Peter F. Cohn

Authors
  1. Peter F. Cohn
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cohn, P.F. Treatment of Chronic Myocardial Ischemia: Rationale and Treatment Options. Cardiovasc Drugs Ther 12 (Suppl 3), 217–223 (1998). https://doi.org/10.1023/A:1007782210758

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1007782210758

Search

Navigation